Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge.

Zheng X, Oduro JD, Boehme JD, Borkner L, Ebensen T, Heise U, Gereke M, Pils MC, Krmpotic A, Guzmán CA, Bruder D, Čičin-Šain L.

PLoS Pathog. 2019 Sep 16;15(9):e1008036. doi: 10.1371/journal.ppat.1008036. eCollection 2019 Sep.

2.

Neutral Lipopolyplexes for In Vivo Delivery of Conventional and Replicative RNA Vaccine.

Perche F, Clemençon R, Schulze K, Ebensen T, Guzmán CA, Pichon C.

Mol Ther Nucleic Acids. 2019 Sep 6;17:767-775. doi: 10.1016/j.omtn.2019.07.014. Epub 2019 Jul 30.

3.

Invariant NKT Cell-Mediated Modulation of ILC1s as a Tool for Mucosal Immune Intervention.

Trittel S, Vashist N, Ebensen T, Chambers BJ, Guzmán CA, Riese P.

Front Immunol. 2019 Aug 7;10:1849. doi: 10.3389/fimmu.2019.01849. eCollection 2019.

4.

The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.

Volckmar J, Knop L, Stegemann-Koniszewski S, Schulze K, Ebensen T, Guzmán CA, Bruder D.

Vaccine. 2019 Aug 14;37(35):4963-4974. doi: 10.1016/j.vaccine.2019.07.019. Epub 2019 Jul 15.

5.

Novel colloidal associations of soyasaponins and lipid components (DPPC, cholesterol) as potential adjuvants for vaccines.

de Groot C, Müsken M, Bleckmann M, Ebensen T, Guzmán CA, Müller-Goymann CC.

Vaccine. 2019 Aug 14;37(35):4975-4986. doi: 10.1016/j.vaccine.2019.07.020. Epub 2019 Jul 15.

PMID:
31320217
6.

The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization.

Ebensen T, Delandre S, Prochnow B, Guzmán CA, Schulze K.

Front Cell Infect Microbiol. 2019 Feb 19;9:31. doi: 10.3389/fcimb.2019.00031. eCollection 2019.

7.

Self-Amplifying Replicon RNA Delivery to Dendritic Cells by Cationic Lipids.

Englezou PC, Sapet C, Démoulins T, Milona P, Ebensen T, Schulze K, Guzman CA, Poulhes F, Zelphati O, Ruggli N, McCullough KC.

Mol Ther Nucleic Acids. 2018 Sep 7;12:118-134. doi: 10.1016/j.omtn.2018.04.019. Epub 2018 May 4.

8.

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development.

Lirussi D, Ebensen T, Schulze K, Reinhard E, Trittel S, Riese P, Prochnow B, Guzmán CA.

J Vis Exp. 2018 Jun 19;(136). doi: 10.3791/57401.

PMID:
29985310
9.

Influenza-Activated ILC1s Contribute to Antiviral Immunity Partially Influenced by Differential GITR Expression.

Vashist N, Trittel S, Ebensen T, Chambers BJ, Guzmán CA, Riese P.

Front Immunol. 2018 Mar 22;9:505. doi: 10.3389/fimmu.2018.00505. eCollection 2018.

10.

Dual dye in-vivo imaging of differentially charged PLGA carriers reveals antigen-depot effect, leading to improved immune responses in preclinical models.

Riehl M, Harms M, Lucas H, Ebensen T, Guzmán CA, Mäder K.

Eur J Pharm Sci. 2018 May 30;117:88-97. doi: 10.1016/j.ejps.2018.01.040. Epub 2018 Feb 13.

PMID:
29408551
11.

Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.

Sanchez Alberti A, Bivona AE, Cerny N, Schulze K, Weißmann S, Ebensen T, Morales C, Padilla AM, Cazorla SI, Tarleton RL, Guzmán CA, Malchiodi EL.

NPJ Vaccines. 2017 Apr 10;2:9. doi: 10.1038/s41541-017-0010-z. eCollection 2017.

12.

Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes.

Landi A, Law J, Hockman D, Logan M, Crawford K, Chen C, Kundu J, Ebensen T, Guzman CA, Deschatelets L, Krishnan L, Tyrrell DLJ, Houghton M.

Vaccine. 2017 Dec 15;35(50):6949-6956. doi: 10.1016/j.vaccine.2017.10.072. Epub 2017 Oct 28.

PMID:
29089195
13.

Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.

Ebensen T, Debarry J, Pedersen GK, Blazejewska P, Weissmann S, Schulze K, McCullough KC, Cox RJ, Guzmán CA.

Front Immunol. 2017 Sep 28;8:1223. doi: 10.3389/fimmu.2017.01223. eCollection 2017.

14.

Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure.

Démoulins T, Ebensen T, Schulze K, Englezou PC, Pelliccia M, Guzmán CA, Ruggli N, McCullough KC.

J Control Release. 2017 Nov 28;266:256-271. doi: 10.1016/j.jconrel.2017.09.018. Epub 2017 Sep 19.

PMID:
28935594
15.

Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.

Schulze K, Ebensen T, Chandrudu S, Skwarczynski M, Toth I, Olive C, Guzman CA.

Nanomedicine. 2017 Nov;13(8):2463-2474. doi: 10.1016/j.nano.2017.08.015. Epub 2017 Sep 5.

PMID:
28887213
16.

Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway.

Lirussi D, Ebensen T, Schulze K, Trittel S, Duran V, Liebich I, Kalinke U, Guzmán CA.

EBioMedicine. 2017 Aug;22:100-111. doi: 10.1016/j.ebiom.2017.07.016. Epub 2017 Jul 19.

17.

Intranasal vaccination with an adjuvanted polyphosphazenes nanoparticle-based vaccine formulation stimulates protective immune responses in mice.

Schulze K, Ebensen T, Babiuk LA, Gerdts V, Guzman CA.

Nanomedicine. 2017 Oct;13(7):2169-2178. doi: 10.1016/j.nano.2017.05.012. Epub 2017 Jun 1.

PMID:
28579436
18.

Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver.

Volckmar J, Gereke M, Ebensen T, Riese P, Philipsen L, Lienenklaus S, Wohlleber D, Klopfleisch R, Stegemann-Koniszewski S, Müller AJ, Gruber AD, Knolle P, Guzman CA, Bruder D.

Sci Rep. 2017 Mar 7;7:43985. doi: 10.1038/srep43985.

19.

Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.

Matos MN, Cazorla SI, Schulze K, Ebensen T, Guzmán CA, Malchiodi EL.

PLoS Negl Trop Dis. 2017 Feb 24;11(2):e0005300. doi: 10.1371/journal.pntd.0005300. eCollection 2017 Feb.

20.

Self-Replicating RNA Vaccine Delivery to Dendritic Cells.

Démoulins T, Englezou PC, Milona P, Ruggli N, Tirelli N, Pichon C, Sapet C, Ebensen T, Guzmán CA, McCullough KC.

Methods Mol Biol. 2017;1499:37-75. Review.

PMID:
27987142
21.

New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.

Schulze K, Ebensen T, Riese P, Prochnow B, Lehr CM, Guzmán CA.

Curr Top Microbiol Immunol. 2016;398:207-234. doi: 10.1007/82_2016_495. Review.

PMID:
27370343
22.

Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines.

Démoulins T, Milona P, Englezou PC, Ebensen T, Schulze K, Suter R, Pichon C, Midoux P, Guzmán CA, Ruggli N, McCullough KC.

Nanomedicine. 2016 Apr;12(3):711-722. doi: 10.1016/j.nano.2015.11.001. Epub 2015 Dec 1.

PMID:
26592962
23.

Modeling Influenza Virus Infection: A Roadmap for Influenza Research.

Boianelli A, Nguyen VK, Ebensen T, Schulze K, Wilk E, Sharma N, Stegemann-Koniszewski S, Bruder D, Toapanta FR, Guzmán CA, Meyer-Hermann M, Hernandez-Vargas EA.

Viruses. 2015 Oct 12;7(10):5274-304. doi: 10.3390/v7102875. Review.

24.

Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination.

Mittal A, Schulze K, Ebensen T, Weissmann S, Hansen S, Guzmán CA, Lehr CM.

J Control Release. 2015 May 28;206:140-52. doi: 10.1016/j.jconrel.2015.03.017. Epub 2015 Mar 18.

PMID:
25795506
25.

Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation.

Mittal A, Schulze K, Ebensen T, Weißmann S, Hansen S, Lehr CM, Guzmán CA.

Nanomedicine. 2015 Jan;11(1):147-54. doi: 10.1016/j.nano.2014.08.009. Epub 2014 Sep 6.

PMID:
25200611
26.

Pegylated bisacycloxypropylcysteine, a diacylated lipopeptide ligand of TLR6, plays a host-protective role against experimental Leishmania major infection.

Pandey SP, Chandel HS, Srivastava S, Selvaraj S, Jha MK, Shukla D, Ebensen T, Guzman CA, Saha B.

J Immunol. 2014 Oct 1;193(7):3632-43. doi: 10.4049/jimmunol.1400672. Epub 2014 Sep 5.

27.

Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge.

Sanchez MV, Ebensen T, Schulze K, Cargnelutti D, Blazejewska P, Scodeller EA, Guzmán CA.

PLoS One. 2014 Aug 20;9(8):e104824. doi: 10.1371/journal.pone.0104824. eCollection 2014.

28.

A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.

Neuhaus V, Chichester JA, Ebensen T, Schwarz K, Hartman CE, Shoji Y, Guzmán CA, Yusibov V, Sewald K, Braun A.

Vaccine. 2014 May 30;32(26):3216-22. doi: 10.1016/j.vaccine.2014.04.011. Epub 2014 Apr 13.

29.

Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties.

Gurramkonda C, Zahid M, Nemani SK, Adnan A, Gudi SK, Khanna N, Ebensen T, Lünsdorf H, Guzmán CA, Rinas U.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 1;940:104-11. doi: 10.1016/j.jchromb.2013.09.030. Epub 2013 Sep 27.

PMID:
24141044
30.

Vaccine adjuvants: key tools for innovative vaccine design.

Riese P, Schulze K, Ebensen T, Prochnow B, Guzmán CA.

Curr Top Med Chem. 2013;13(20):2562-80. Review.

PMID:
24066891
31.

Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization.

Mittal A, Raber AS, Schaefer UF, Weissmann S, Ebensen T, Schulze K, Guzmán CA, Lehr CM, Hansen S.

Vaccine. 2013 Jul 25;31(34):3442-51. doi: 10.1016/j.vaccine.2012.12.048. Epub 2013 Jan 2.

PMID:
23290836
32.

Toll-like receptor-2 agonist-allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia.

Krishnaswamy JK, Jirmo AC, Baru AM, Ebensen T, Guzmán CA, Sparwasser T, Behrens GM.

Am J Respir Cell Mol Biol. 2012 Dec;47(6):852-63. doi: 10.1165/rcmb.2011-0414OC. Epub 2012 Sep 6.

PMID:
22962064
33.

Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology.

Yevsa T, Ebensen T, Fuchs B, Zygmunt B, Libanova R, Gross R, Schulze K, Guzmán CA.

Environ Microbiol. 2013 Jan;15(1):64-76. doi: 10.1111/j.1462-2920.2012.02779.x. Epub 2012 Jun 7.

PMID:
22676396
34.

Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP.

Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzmán CA, Cox RJ.

PLoS One. 2011;6(11):e26973. doi: 10.1371/journal.pone.0026973. Epub 2011 Nov 1.

35.

Bis-(3',5')-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant.

Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzmán CA.

Vaccine. 2011 Jul 18;29(32):5210-20. doi: 10.1016/j.vaccine.2011.05.026. Epub 2011 May 25.

PMID:
21619907
36.

Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.

Madhun AS, Haaheim LR, Nøstbakken JK, Ebensen T, Chichester J, Yusibov V, Guzman CA, Cox RJ.

Vaccine. 2011 Jul 12;29(31):4973-82. doi: 10.1016/j.vaccine.2011.04.094. Epub 2011 May 18.

PMID:
21600260
37.

The NKT cell ligand αgalactosylceramide suppresses allergic airway inflammation by induction of a Th1 response.

Knothe S, Mutschler V, Rochlitzer S, Winkler C, Ebensen T, Guzman CA, Hohlfeld J, Braun A, Muller M.

Vaccine. 2011 Jun 6;29(25):4249-55. doi: 10.1016/j.vaccine.2011.03.068. Epub 2011 Apr 2.

PMID:
21463684
38.

Local treatment with BPPcysMPEG reduces allergic airway inflammation in sensitized mice.

Knothe S, Mutschler V, Rochlitzer S, Winkler C, Ebensen T, Guzman CA, Hohlfeld J, Braun A, Muller M.

Immunobiology. 2011 Jan-Feb;216(1-2):110-7. doi: 10.1016/j.imbio.2010.05.003. Epub 2010 May 8.

PMID:
20619481
39.

Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices.

Switalla S, Lauenstein L, Prenzler F, Knothe S, Förster C, Fieguth HG, Pfennig O, Schaumann F, Martin C, Guzman CA, Ebensen T, Müller M, Hohlfeld JM, Krug N, Braun A, Sewald K.

Toxicol Appl Pharmacol. 2010 Aug 1;246(3):107-15. doi: 10.1016/j.taap.2010.04.010. Epub 2010 Apr 29.

PMID:
20434477
40.

The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.

Prajeeth CK, Jirmo AC, Krishnaswamy JK, Ebensen T, Guzman CA, Weiss S, Constabel H, Schmidt RE, Behrens GM.

Eur J Immunol. 2010 May;40(5):1272-83. doi: 10.1002/eji.200939790.

41.

The member of the cyclic di-nucleotide family bis-(3', 5')-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant.

Libanova R, Ebensen T, Schulze K, Bruhn D, Nörder M, Yevsa T, Morr M, Guzmán CA.

Vaccine. 2010 Mar 2;28(10):2249-2258. doi: 10.1016/j.vaccine.2009.12.045. Epub 2010 Jan 7. Erratum in: Vaccine. 2010 Apr 30;28(20):3625.

PMID:
20060510
42.

Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.

Ebensen T, Guzmán CA.

Adv Exp Med Biol. 2009;655:171-88. doi: 10.1007/978-1-4419-1132-2_13. Review.

PMID:
20047042
43.

A Toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to Timothy grass pollen antigens.

Fuchs B, Knothe S, Rochlitzer S, Nassimi M, Greweling M, Lauenstein HD, Nassenstein C, Müller M, Ebensen T, Dittrich AM, Krug N, Guzman CA, Braun A.

Int Arch Allergy Immunol. 2010;152(2):131-9. doi: 10.1159/000265534. Epub 2009 Dec 16.

44.

The toll-like receptor 2/6 ligand MALP-2 reduces the viability of Mycobacterium tuberculosis in murine macrophages.

Palma C, Iona E, Ebensen T, Guzman CA, Cassone A.

Open Microbiol J. 2009 Apr 3;3:47-52. doi: 10.2174/1874285800903010047.

45.

HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats.

Bosch V, Pfeiffer T, Devitt G, Allespach I, Ebensen T, Emerson V, Guzman CA, Keppler OT.

Vaccine. 2009 Apr 6;27(16):2202-12. doi: 10.1016/j.vaccine.2009.02.014. Epub 2009 Feb 13.

PMID:
19428834
46.

The missing link: Bordetella petrii is endowed with both the metabolic versatility of environmental bacteria and virulence traits of pathogenic Bordetellae.

Gross R, Guzman CA, Sebaihia M, dos Santos VA, Pieper DH, Koebnik R, Lechner M, Bartels D, Buhrmester J, Choudhuri JV, Ebensen T, Gaigalat L, Herrmann S, Khachane AN, Larisch C, Link S, Linke B, Meyer F, Mormann S, Nakunst D, Rückert C, Schneiker-Bekel S, Schulze K, Vorhölter FJ, Yevsa T, Engle JT, Goldman WE, Pühler A, Göbel UB, Goesmann A, Blöcker H, Kaiser O, Martinez-Arias R.

BMC Genomics. 2008 Sep 30;9:449. doi: 10.1186/1471-2164-9-449.

47.

A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.

Schulze K, Staib C, Schätzl HM, Ebensen T, Erfle V, Guzman CA.

Vaccine. 2008 Dec 2;26(51):6678-84. doi: 10.1016/j.vaccine.2008.09.006.

PMID:
18805454
48.

Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.

Ebensen T, Guzmán CA.

Hum Vaccin. 2008 Jan-Feb;4(1):13-22. Epub 2008 Jan 10. Review.

PMID:
18376145
49.

Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi.

Cazorla SI, Becker PD, Frank FM, Ebensen T, Sartori MJ, Corral RS, Malchiodi EL, Guzmán CA.

Infect Immun. 2008 Jan;76(1):324-33. Epub 2007 Oct 29.

50.

A pegylated derivative of alpha-galactosylceramide exhibits improved biological properties.

Ebensen T, Link C, Riese P, Schulze K, Morr M, Guzmán CA.

J Immunol. 2007 Aug 15;179(4):2065-73.

Supplemental Content

Loading ...
Support Center